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1. Introduction 
 During the recent years, the interest in the purinergic system has been gaining importance, 
and this interest is not accidental. The purinergic system is so far known to be involved in 
several physiological conditions in mammals, becoming a potential therapeutic target for 
the treatment of many pathologies and disorders. One of the physiological roles is the 
control of pain. This chapter will emphasize adenosine receptors (P1) and its activation and 
inhibition by adenosine and by specific agonists or antagonists in the treatment of pain. 
Although most of the studies quoted in this chapter were performed in animals, in this 
chapter we will use the expression analgesia instead of antinociception (term used to report 
pain in animals) to simplify our communication. Some drugs that act on adenosine receptors 
have presented interesting results in clinical studies of pain and other drugs are under 
investigation. Of note, it has recently been shown that inosine, a metabolite of adenosine, 
has significant analgesic effects in several pre-clinical models of pain. Thus, the inosine can 
be an important tool in this area of study or even a molecule of interest for future 
pharmacological approaches, knowing that such as adenosine, it is produced endogenously 
and devoid of side effects in normal doses. In addition, new approaches using enzyme 
inhibitors of the purinergic system or supplies of adenosine suggest alternatives to 
potentiate and lasting analgesic effects of adenosine or analogs. Moreover, the release of 
purines and the adenosine A1 receptor activation are essential to analgesia by acupuncture 
in mice. Thus, purinergic system will be the target of many future pain-treatment 
researches. After all, it is indispensable to students and biomedical professionals to know 
and understand basic concepts about this endogenous system.  
2. Involvement of purinergic system in pain  
2.1 Purinergic receptors: History and involvement in pain 
Purinergic receptors history began when Drury and Szent-Györgi described the potent 
actions of purines adenine and adenosine on the heart and blood vessels (Drury & Szent-
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Györgi, 1929). Later, in 1970 Burnstock presented evidence that ATP acted as a 
neurotransmitter in nonadrenergic noncholinergic (NANC) nerves supplying the gut, and 
finally, in 1972, the purinergic neurotransmission hypothesis was proposed (Burnstock, 
1972). With these discoveries, the number of publications involving ATP and its metabolites 
grew quickly and continues to do so (Figure 1).  
 
 
 
Fig. 1. Total of publications with keywords ATP, Adenosine (Ado), Adenosine Receptors 
(Ado Rec) and Inosine (Ino) from 1930 until 2010. Source: Pubmed 
Afterwards, it was established that the ATP acted as a cotransmitter with classical 
transmitters in both the peripheral nervous system and in the central and that purines are 
also powerful extracellular messengers to non-neuronal cells (Burnstock & Knight, 2004). 
Burnstock, in 1978, provided the basis for the distinction of two classes of purinergic 
receptors; adenosine-sensitive P1 and ATP-sensitive P2 receptor classes.  In 1985, Burnstock 
and Kennedy proposed a basis for distinguishing two types of P2 purinoceptors, namely, 
P2X and P2Y. Afterwards, in 1994 Abbracchio and Burnstock through studies of 
transduction mechanisms and cloning of both P2X and P2Y receptors put forward a new 
nomenclature system, naming them, P2X ionotropic ligand-gated ion channel receptors and 
P2Y metabotropic G protein-coupled receptors, respectively. Currently, seven subtypes of 
P2X receptors (P2X1, P2X2, P2X3, P2X4, P2X5, P2X6, P2X7) and eight subtypes of P2Y receptors 
(P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14) are clearly established. P2X and P2Y 
receptor activation by ATP stimulates cellular excitability, augments the release of excitatory 
amino acids, and consequently initiates pain responses (Burnstock, 2007; Burnstock & 
Williams, 2000). In the context of pain neurotransmission, preclinical studies show us that 
activation of P1 receptors by adenosine decreases pain, inflammation, and cellular 
excitability (McGaraughty & Jarvis, 2006). During the 80’s and 90’s research evaluating 
purinergic system in pain rocketed (Figure 2).  
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Fig. 2. Total of publications with keywords ATP, Adenosine (Ado), Adenosine Receptors 
(AdoR) and Inosine (Ino) plus Pain from 1930 until 2010. Source: Pubmed 
3. Adenosine receptors and pain  
3.1 Adenosine receptors  
Adenosine is the natural ligand of P1 receptors, also called adenosine receptors. All these 
receptors are G-protein coupled and are divided according to pharmacological, biochemical 
and molecular properties into four subtypes: A1, A2A, A2B and A3. Each receptor has a 
distinct distribution and due to its special features, has distinct roles as well (Burnstock et 
al., 2011; Fredholm et al., 2011; Ralevic & Burnstock, 1998; Ribeiro et al., 2002; Sawynok & 
Liu, 2003). Adenosine receptors were cloned and characterized in several mammal species 
(Burnstock, 2008).  
3.2 Distribution of adenosine receptors 
Adenosine receptors are present in several species and in distinct tissues. However, their 
distribution is quite irregular and different among species and mainly among tissues 
(Fredholm et al., 2011). A1 receptor (A1R) is a ubiquitous receptor. In the central nervous 
system, it is distributed in the cerebellum, cerebral cortex, hippocampus, thalamus, spinal 
cord (substantia gelatinosa), brain stem, olfactory bulb and other central sites. Peripherally 
A1R distribution is less wide than centrally, but there is a considerable density of A1R in 
sensory afferent fibers, mainly on C-fibers which are responsible for receiving and 
conducting the painful stimuli (Dixon et al., 1996; Sawynok, 2009). A2A receptor (A2AR)has an 
even distribution between central and peripheral nervous system, but mainly in central 
structures as nucleus accumbens, putamen, caudate and in immune tissues, vascular smooth 
muscle, endothelium, platelets and sensory neurons (Dixon et al., 1996; Fredholm, 1995; 
Ralevic & Burnstock, 1998; Sawynok, 2009). A2B receptor (A2BR) is also a ubiquitous receptor 
and it has been found either in many central or peripheral tissues. However, A2BR density is 
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very low and it has been found in great density only in bowel and bladder. A3 receptors 
(A3R)are widely distributed in several mammals, however, few studies have indicated 
specific roles for this receptor (Dixon et al., 1996; Ralevic & Burnstock, 1998; Salvatore et al., 
1993). 
3.3 General adenosine receptor signaling 
All adenosine receptors are coupled to G-protein. Nevertheless there are many kinds of G-
protein and each one may activate a distinct pathway. Thus, the four adenosine receptors 
can stimulate or inhibit several pathways and consequently exert many physiological 
actions (Jacobson & Gao, 2006; Ralevic & Burnstock, 1998). We show below the main 
signaling characteristics of each adenosine receptor.  
3.3.1 A1 receptor signaling 
A1R is coupled to Gi/0 protein family which is pertussis toxin-sensitive. Most of the 
biological effects induced by A1R activation are due to inhibition of cAMP second messenger 
(Burnstock, 2007; Jacobson & Gao, 2006; Ralevic & Burnstock, 1998; Sawynok, 1998) (Figure 
3 and Table 1).  
 
Fig. 3. Adenosine A1 receptors and its main pathways. A1R, adenosine A1 receptor; AC, 
adenylate cyclase;  cAMP, cyclic adenosine monophosphate; DAG, diacylglicerol; ERK1/2, 
extracellular signal-regulated kinases 1 and 2; IP3, inositol triphosphate; K+, potassium 
channels; MAPK, mitogen-activated protein kinase; MEK, MAPK and ERK kinase; PKA, 
protein kinase;  PLC, phospholipase C. 
Beta and gamma subunities of A1R, when activated stimulate phospholipase C (PLC). 
Activation of PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol 
(DAG) and inositol 1,4,5-trisphosphate (IP3) leading to increased levels Ca+2. Moreover, the 
enhancement of intracellular calcium can induce some enzymes such as protein kinase C 
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(PKC), phospholipase D (PLD), phospholipase A2 (PLA2) and others. Furthermore, 
adenosine or adenosine agonists can activate K+ channels (Jacobson & Gao, 2006; Megson et 
al., 1995; Ralevic & Burnstock, 1998). A1R activation can also activate PI3K and MAPK 
pathways, more specifically ERK1/2 and MEK inducing gene expression changes and glial 
cell protection (Boison et al., 2010; Shulte & Fredholm, 2003). 
3.3.2 A2A receptor signaling 
A2AR is coupled to Gs (the most part) and Golf protein (mainly in striatum). The main 
intracellular event after activation of these proteins is adenylate cyclase activation followed 
by cAMP production enhancement (Table 1).  
 
 
Table 1. Adenosine receptors signaling. Adapted from Ralevic and Burnstock, 1998; 
Sawynok and Liu, 2003; Jacobson and Guao, 2006. 
The increasing of cAMP stimulates cAMP-dependent kinase (PKA). Thus, PKA becomes 
able to activate several pathways through PKC, calcium channels, potassium channels, 
cAMP responsive element-binding (CREB), MAPK, PLC activation (Burnstock, 2007; Cunha 
et al., 2008; Fredholm et al., 2003, 2007; Jacobson & Gao, 2006; Ralevic & Burnstock, 1998).   
3.3.3 A2B receptor signaling 
Through Gs and Gq activation A2B receptor induces adenylate cyclase and PLC. In humans, 
A2BR can increase intracellular calcium by IP3 activation. Moreover, the arachidonic acid 
pathway is also involved in A2BR signaling (Feoktistov & Biaggioni, 2011; Jacobson & Gao, 
2006; Peakman and Hill, 1994).  
3.3.4 A3 receptor signaling 
A3R like A1R is coupled to Gi/0 and also to Gq/11 protein. Its main signaling transduction is 
the inhibition of adenylate cyclase and stimulation of PLC, IP3, DAG, PKC and PLD. Also, 
like other adenosine receptors, A3R activates MAPK pathway, mainly ERK1/2 (Abbracchio 
et al., 1995; Armstrong & Ganote, 1994; Palmer et al., 1995; Shneyvays et al., 2004). 
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3.4 A1 receptors and pain 
A1R is the main responsible for inducing analgesia among the adenosine receptors 
(Burnstock et al., 2011; Sawynok, 1998; Sawynok & Liu, 2003). It has been shown that A1R is 
widely distributed in the dorsal spinal cord, mainly in lamina II (substantia gelatinosa) 
(Choca et al., 1988; Horiuchi et al., 2010; Sawynok, 1998). In this site, many afferent sensory 
nerve have connections with post-synaptic neurons. Also, A1R are localized in the 
descending projection within dorsal horn (Choca et al., 1988).  
3.4.1 Effects of A1 receptor activation in acute pain 
There are several published data showing the important effect of A1R in controlling acute 
pain (review see Jacobson & Gao, 2006; Sawynok, 1998). Moreover, it has been shown that 
systemic administration of various A1R agonists can produce analgesic effect in several 
models of acute pain in animals (Gong et al., 2010; Sawynok, 1998). Probably, these effects 
are caused by peripheral, supraspinal and mostly by spinal A1R. In mice lacking A1R 
(knockout animals) a lower pain threshold was observed in hyperalgesia tests (Wu et al., 
2005). Further, analgesic effect induced by intrathecal adenosine was abolished as well as 
the  increase of thermal hyperalgesia in A1R knockout mice (Johansson et al., 2001).  
Several studies published show that intrathecal injection of A1R agonists cause analgesia in 
various animal models of acute pain, including tail flick, tail immersion, hot-plate, formalin, 
acetic acid, capsaicin models and others (Nascimento et al., 2010; Song et al., 2011; Zahn et 
al., 2007). 
A1R is also found in primary afferent neurons and in the cell body and the dorsal root 
ganglia (Lima et al., 2010; Sawynok, 2009), then it has an important role in modulation of 
peripheral pain. Many studies have shown that administration of A1R agonists into the paw 
of animals causes an analgesic effect in several animal models of pain. It has been shown 
that A1R activation in the periphery inhibits formalin-induced pain and reduces hyperalgesia 
induced by PGE2 (Karlsten et al., 1992; Taiwo & Levine, 1990). Further, when the peripheral 
adenosine A1R is activated, it triggers the NO/cGMP/PKG/KATP intracellular signaling 
pathway and then inhibits pain (Lima et al., 2010). Moreover, A1R agonists reduce the 
thermal hyperalgesia, but not mechanical allodynia, caused by sciatic nerve injury. The 
thermal hyperalgesia is mediated by C fibers and mechanical allodynia, in turn, is mediated 
by A fibers, which demonstrates the presence of A1R in C but not in A fibers (Sawynok, 
2009). 
3.4.2 A1 receptor and chronic pain 
Several authors have shown that different agonists of A1R are able to reduce distinct  
kinds of chronic pain. The agonist R-PIA inhibits mechanical allodynia induced by spinal 
nerve ligation in rats (Hwang et al., 2005; Song et al., 2011). In addition, R-PIA also reduces 
thermal pain threshold in rats that underwent an injury in the spinal cord (Horiuchi et al., 
2010).  Moreover, other mechanisms are generally involved in analgesic effect in chronic 
pain induced by A1R activation, such as inhibition of glutamate release. Another A1R agonist, 
CPA, when given to rats, inhibits pain induced by arthritis and pain induced by neuropathy 
(Curros-Criado & Herrero, 2005). Also, in experiments with A1R knockout mice it has been 
observed that these animals present a lower pain threshold than wild-type animals in 
inflammatory and neuropathic pain models (Wu et al., 2005).  
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3.4.3 Interactions between A1 receptor and opioid system 
There is a strong relationship between opioidergic and adenosinergic systems in pain 
modulation. Morphine and other opioids are able to release adenosine (Sawynok et al., 1989; 
Sweeney et al., 1987a,b; Sweeney et al., 1989). Adenosine or analog administration combined 
with opioids enhances the analgesic effect of the latter (DeLander & Hopkins, 1986). 
However, administration of methylxanthines, adenosine receptor antagonists, can augment, 
decrease or have no effect on analgesic activity of opioids (Sawynok, 2011). In addition, A1R 
can undergo dimerization with µ receptor in afferents neurons and induce the decrease of 
cAMP production (Sawynok, 1998).  
3.4.4 Interactions among A1 receptor and other receptors in pain mechanisms 
A1R is able to dimerize with alpha-2-adrenergic receptor. Also, it has been shown that 
serotonin releases adenosine from primary afferents and that A1R receptor antagonist blocks 
serotonin analgesic actions, suggesting a close involvement between adenosinergic and 
serotoninergic systems in pain modulation (Sawynok, 1998). 
3.4.5 A1 agonists/antagonists 
Methylxanthines (caffeine included) are natural antagonists of adenosine A1R and A2AR. 
However, the main selective agonists/antagonists to A1R are synthetics. Some of them are 
listed in Table 2. 
 
Table 2. Principal adenosine A1 receptor agonists and antagonists.  
3.5 A2A receptors and pain  
Taiwo & Levine (1990) demonstrated clear distinct effects of A1R and A2AR activation in 
peripheral pain. They showed that, in peripheral sites, A1R mediates analgesia while A2AR 
facilitates painful perception. In addition, other studies also showed that peripheral A2AR 
activation induced pain (Doak & Sawynok, 1995; Li et al., 2010; Taiwo & Levine, 1990). 
However, systemically and spinally, the role of A2AR is not entirely clear. Some publications 
have demonstrated that A2AR activation induces pain (Bastia et al., 2002; Hussey et al., 2007). 
On the other hand, other authors have showed a reduction of pain when A2AR is activated 
(By et al., 2011; Borghi et al., 2002; Yoon et al., 2005). These controversial results might be 
associated with A2AR intracellular signaling. A2AR activation induces cAMP increased 
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production (it can cause pain) and also K+ channels opening (it can inhibit pain) (Jacobson & 
Gao, 2006; Regaya et al., 2004; Sawynok, 1998).  
A2AR knockout animals are less sensitive to pain, suggesting that A2AR is a pain facilitator in 
acute (Hussey et al., 2007) and chronic pain (Bura et al., 2008). Bura and coworkers (2008) 
also demonstrated that microglia and astrocytes expression was higher in wild-type A2AR 
animals than in A2AR knockout animals. Also, A2AR located in glial cells is responsible for the 
release of inflammatory mediators that induce and maintain chronic pain (Boison et al., 
2010). Thus, A2AR blockade might be an interesting approach for future treatments of 
neuropathic and chronic pain. Meantime, also in chronic pain exists distinct results about 
A2AR. A report showed that only one spinal injection of A2AR agonist was able to induce 
analgesia during several days in rats undergoing neuropathic pain (Loram et al., 2009).  
After all, it is clear that A2AR is involved in pain modulation. However, more studies are 
necessary to precisely explain how this receptor works in distinct situations, only then it will 
be possible to make clinical approaches.  
3.6 A2B receptors and pain 
Few studies have been evaluating the A2BR role in pain. Most part of these studies showed 
that A2BR facilitates pain transmission, because A2BR antagonists have reduced pain (Abo-
Salem et al., 2004; Bilkei-Gorzo et al., 2008; GodFrey et al., 2006). A2BR antagonist reduced 
thermal hyperalgesia and was able to potentiate the analgesic effect caused by morphine 
and acetaminophen (Abo-Salem et al., 2004; Godfrey et al., 2006). Also, the blockade of A2BR 
presented an analgesic effect in inflammatory pain (Bilkei-Gorzo et al., 2008). 
3.7 A3 receptors and pain  
Similar to A2BR, adenosine A3R is not an interesting target to pain relief. However, A3R is 
implicated in pathological conditions such as ischemic diseases and in inflammation (for 
review see Borea et al., 2009). Regarding pain, there are few studies evaluating A3R role. 
Sawynok and colleagues (1997) showed that A3R activation causes pain and paw oedema 
through release of histamine and serotonin. A3R knockout animals presented an increased 
pain threshold in some models of pain but not difference in others (Fedorova et al., 2003; 
Wu et al., 2002). A3R might be an interesting target to inflammatory and autoimmune 
diseases, but not to pain states.  
3.8 Novel approaches in pain management involving adenosine receptors 
3.8.1 Management of adenosine receptors by metabolism modulation 
The first report showing that adenosine kinase (AK) inhibition reduces behaviour associated 
to pain was published by Keil and DeLander, 1992. AK inhibitors are able to decrease pain 
levels when given peripherally or sistemically (Kowaluk et al., 1999; Lynch et al., 1999; 
Sawynok, 1998). Moreover, these inhibitors are efficacious against acute and chronic pain 
(Kowaluk et al., 2000; Lynch et al., 1999; McGaraughty et al., 2005; Poon & Sawynok, 1998, 
1999; Suzuki et al., 2001). Another enzyme that regulates adenosine level is adenosine 
deaminase (ADA), that converts adenosine to inosine (Sawynok, 1998). However, the 
analgesic effect caused by ADA inhibition is not so clear yet. It has been showed that 
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inhibitors of ADA itself are able to cause analgesia in determined animal models (Poon & 
Sawynok, 1999), but not in others (Keil & DeLander, 1992, 1994). 
Coadministration of AK and ADA inhibitors potentiates the analgesic effect of the former 
(Poon & Sawynok, 1999). Also, adenosine effect is synergically augmented by 
coadministration of ADA inhibitor (Keil & DeLander, 1994). Distinct effects between AK 
inhibitors and ADA inhibitors might be because adenosine has a higher affinity by AK than 
ADA (Arch & Newsholme, 1978). In this point of view, AK seems to be the most important 
enzyme to regulate adenosine endogenous levels. 
3.8.2 Analgesic effect by supply of purinergic substrates 
Ecto-5’-nucleotidase (NT5E) is an enzyme located in the cell membrane that catalyzes the 
extracellular conversion of adenosine monophosphate (AMP) into adenosine in several 
tissues, included dorsal root ganglia (DRG) and substantia gelatinosa (Zylka, 2011). Recent 
studies have demonstrated that the analgesic effect of AMP combined with an AK inhibitor 
halved in NT5E knockout animals and is totally reversed in A1R knockout animals (Sowa et 
al., 2010a). These results inspired another study that evaluated whether exogenous supply of 
NT5E (increases supply of adenosine) could induce a long lasting analgesic effect. NT5E 
presented effects that lasted for 2 days in models of inflammatory and chronic pain. Both 
effects were dependent on A1R (Sowa, 2010b). Hence, the supply of enzymes that generate 
adenosine is a new interesting approach that may be used in studies to treat chronic pain. 
3.8.3 Involvement of adenosine receptors in acupuncture pain relief 
In an elegant study published in 2010, Goldman and colleagues showed that analgesia 
induced by acupuncture depends on purine release, such as ATP, ADP, AMP and 
adenosine. In addition, it has been showed that A1R agonist replicates the acupuncture 
effect. Also, in A1R knockout animals, acupuncture did not present analgesia. Moreover, 
inhibition of adenosine deaminase prolonged the analgesic effect of acupuncture in mice 
(Goldman et al., 2010). It is interesting to mention that caffeine, the most widely used drug 
across the world in beverages such as teas, coffee, mate, soft drinks, energy drinks and 
others is an antagonist of adenosine receptors. Therefore, patients in treatment with 
acupuncture should not drink these caffeine beverages, because caffeine might reduce the 
acupuncture analgesic effect (for review see Zylka, 2010). 
4. Inosine and pain 
4.1 Inosine within of purinergic system 
ATP is the main molecule of purinergic system. Inside the cell, ATP may be bi-directionally 
converted into AMP. AMP is  broken down into adenosine. Adenosine may be converted 
back into AMP through phosphorylation by AK. Moreover, adenosine might leave the cell 
by nucleoside transporter (NT). Inside the cell, adenosine deaminase is responsible for the 
conversion from adenosine to inosine. Outside the cell, this conversion is performed by ecto-
adenosine kinase or even adenosine deaminase. Inosine is a substrate to purine nucleoside 
phosphorylase (PNP), leading to hypoxanthines as its products. Hypoxanthines are 
converted into xanthines and afterwards to uric acid by xanthine oxidase (Figure 4) (See 
review Sawynok & Liu, 2003).  
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Fig. 4. Purinergic metabolism and its main molecules and enzymes. A1, adenosine A1 
receptor; A2A, adenosine A2A receptor; A2B, adenosine A2B receptor; A3, adenosine A3 
receptor ADA, adenosine deaminase; AK, adenosine kinase; AMP, adenosine 
monophosphate; ATP, adenosine triphosphate; ENT, equilibrative nucleoside transporter; 
HXT, hypoxanthines; NT5E, ecto-5’nucleotidase; P2X, purine P2X receptor; P2Y, purine P2Y 
receptor; PNP, purine nucleoside phosphorilase. 
Thus, inosine is one among many molecules in purinergic system. However, inosine has 
specific roles in several physiological states, we will show some functions and discuss the 
role of inosine in pain control in next sections. 
4.2 Inosine physiological roles 
In recent decades, many physiological roles for inosine have been  shown. During the 70’s, 
Aviado demonstrated that inosine exerts cardiotonic actions, such as preventing negative 
inotropic effect and increasing coronary vasodilatation (Aviado, 1978). Also, inosine 
presents several effects on axonal growth, such as axon growth induction and damaged 
neurons stimulation (Benowitz et al., 1999, 2002; Chen et al., 2002). Inosine also induces a 
regrowth in axotomized retinal ganglion cells in rats (Wu et al., 2003). These data indicate 
that inosine may constitute a new approach to treat the injured or degenerated nerves in 
central or peripheral nervous system. Despite of cardiovascular and axonal growth effects, 
the inflammatory effects of inosine are the most studied. Inosine has significant anti-
inflammatory effects in several in vivo and in vitro models of inflammation (Gomez & 
Sitkovsky, 2003; Haskó et al., 2000; Marton et al., 2001; Schneider et al., 2006). These effects 
seem to be mediated by A1R, A2R and A3R (Gomez & Sitkovsky, 2003; Haskó et al., 2000, 
2004).    
4.3 Inosine effect on acute pain 
Inosine has analgesic action when administered by different routes (i.e. intraperitoneal, oral, 
intrathecal or intracerebroventricular) against pain induced by acetic acid (Nascimento et al., 
2010). Of note, inosine also inhibits pain induced by formalin. Formalin test induces 2 
distinct types of pain, neurogenic phase (acute pain) and inflammatory phase (inflammatory 
pain). Inosine is not able to relieve pain in neurogenic phase. However, inosine reduces 
nearly totally the inflammatory pain in formalin test (Nascimento et al., 2010). The effects of 
inosine in this model of pain extended the acetic acid data because formalin is a more 
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specific model. Therefore, these results indicate that inosine is able to prevent and reduce 
pain induced by inflammatory mediators. In this way, inosine may be inhibiting the 
synthesis or release of several neurotransmitters and mediators involved in pain conditions 
(Nascimento et al., 2010). We can also conclude that inosine is able to inhibit pain induced 
by central facilitation. Therefore, inosine increases pain threshold and it may be useful to 
treat some kinds of pain injury that result from a central sensitization. Adenosine receptors 
distribution on substantia gelatinosa, mainly A1R and A2AR could explain how inosine acts in 
this case (Sawynok, 1998; Sawynok & Liu, 2003). Inosine also presents a significant and 
dose-related inhibition of pain induced by glutamate (acute pain model) injection into the 
paw of mice (Nascimento et al., 2010).   
4.4 Inosine effects on chronic pain 
The data described in literature strongly suggests that inosine may have an important effect 
in controlling chronic pain, since it has anti-inflammatory effect and can reduce acute pain. 
In fact, Nascimento and colleagues (2010) demonstrated that acute administration of inosine, 
intraperitoneally, was able to inhibit chronic inflammatory pain induced by CFA in mice, 
being effective up to 4 hours after administration. The CFA is responsible for inducing 
chronic inflammation by stimulating the body's immune response, this response is mediated 
by the synthesis and release of cytokines and inflammatory mediators (Zhang et al., 2011). 
In the study published by Nascimento and colleagues (2010), inosine was effective against 
mechanical and thermal allodynia induced by partial sciatic nerve ligation (PSNL) up to 4 
hours after treatment by intraperitoneal route. Further, in another experiment, inosine was 
given daily for until 22 days and it also presented significant analgesic effect. Pain induced by 
PSNL is very strong and may last for weeks (Ueda, 2006). Animal models of neuropathic pain 
induce many functional and biochemical changes in local injury site. After the surgery there is 
the release of multiple inflammatory and pain mediators which in turn, may also be present in 
other areas involved and affected by sciatic nerve, as spinal cord and brain (Bridges et al., 2001; 
Ji & Woolf, 2001; Inoue et al., 2004; Ueda, 2006). Inosine activity in this kind of pain may 
indicate a promising molecule to new studies, because inosine might have a longer half-life 
than adenosine and admittedly does not have toxic or side effects.  
4.5 Adenosine receptors involved in analgesic effects of inosine 
A1R has been considered the main receptor responsible for analgesic effect among adenosine 
receptors (Burnstock, 2007; Sawynok, 1998). A1R is also the main receptor involved in inosine 
analgesic effect. Both A1R antagonists DPCPX and 8-PT were able to reverse the inosine 
action. Inosine in a direct or indirect way activates A1R to induce analgesia (Nascimento et 
al., 2010). Other studies have showed that adenosine receptor antagonists block in vivo and 
in vitro inosine effects (Haskó et al., 2000) and adenosine receptor knockout animals do not 
present immunoprotective effects of inosine (Gomez & Sitkovsky, 2003). Thus, it is clear that 
the A1R activation is essential for  inosine to exert its  effect (Figure 5). 
Involvement of A2AR in pain is quite controversial. Some studies show that A2AR blockade 
leads to analgesic effect (Borghi et al., 2002; Yoon et al., 2005) while other studies 
demonstrate that the blockade or deletion of A2AR causes pain relief (Bastia et al., 2002; 
Ledent et al., 1997). Inosine activates A2AR to induce analgesia, at least in the acetic acid 
www.intechopen.com
 Pharmacology 
 
638 
model (Nascimento et al., 2010). However, the participation of A2AR receptor in inosine 
analgesia in other pain animal models might be different or does not exist. Moreover, the 
A2AR involvement on inosine effect can occur due to its anti-inflammatory profile (Milne & 
Palmer, 2011) and due to activation of the K+ channels (Regaya et al., 2004). 
 
Fig. 5. Principal mechanisms of inosine antinociception. A1R, adenosine A1 receptor; A2AR, 
adenosine A2A receptor, cAMP, cyclic adenosine monophosphate; K+, potassium channels; 
PKC, protein kinase C.   
A2BR and A3R adenosine receptors do not have significant role in pain transmission or 
modulation (Sawynok, 1998). Although it has been shown that inosine binds to A3R, it seems 
that A2BR and A3R receptors are not involved in inosine analgesic effect (Nascimento et al., 
2010).  
4.5.1 Does inosine binds to adenosine receptor?  
Few studies have evaluated if inosine binds to adenosine receptor. Jin and co-workers 
demonstrated that inosine binds to A3R in mast cells, but not to A1R or A2AR (Jin et al., 1997). 
In 2001, Fredholm’s group observed that inosine weakly bound to A1R and A3R, but not to 
A2R (Fredholm et al., 2001). Fredholm concluded that inosine could not be considered a 
natural ligand of adenosine receptors. However, because of these few studies and 
considering in vivo studies where adenosine antagonists are able to block inosine effects, it is 
not is possible to affirm whether inosine is or not a natural ligand or a partial agonist of 
adenosine receptors. More studies are necessary to elucidate this issue.  
4.6 Intracellular signalling involved in analgesic effects of inosine 
The intracellular signaling involved in analgesic action of inosine is yet not entirely 
elucidated. Assuming that inosine effects depend on adenosine receptors, A1R and A2AR, we 
can consider that adenosine receptors signaling pathways are the major effectors of this 
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effect. As fully mentioned previously, A1R is coupled to Gi/0 protein. A1R signaling causes 
downstream inhibition of adenylyl cyclase and induction of PLC activity. Further, when A1R is 
activated it causes potassium channel opening, PI3K and MAPK stimulation. All these 
pathways might participate in the inosine analgesic effect (Ansari et al., 2009; Jacobson & Gao, 
2006; Sawynok, 1998; Schulte & Fredholm, 2003). Inosine inhibits the pain caused by PKC 
activator. Thus, at least in part, the analgesic action of inosine depends on PKC inhibition 
(Nascimento et al., 2010), even though it is not clear yet how it happens (Figure 5). Costenla 
and coworkers showed that an adenosine analog that has preference for A2AR is able to inhibit 
sodium current in NMDA receptors (Costenla et al., 1999). This signaling occurring in vivo 
could partially explain how A2AR works in analgesia induced by inosine.  
4.7 Perspectives 
As previously described in this chapter, purinergic system is an important endogenous 
modulator of pain. Hundreds of pre-clinical studies targeting the adenosine receptors 
showed analgesic effect in distinct pain models. Inosine, an endogenous modulator of 
several physiological functions also presents a role in pain transmission. Inosine might be a 
natural activator of adenosine receptors. Also, it can indirectly increase the release or reduce 
the uptake of adenosine, potentiating the effect of its precursor. Thus, understanding how 
inosine acts to induce analgesia may help discover new ways to inhibit pain or new 
therapeutic targets. Moreover, inosine may be a potential molecule to treat pain, and it has a 
great advantage to be devoid of toxic or side effects because it has been used clinically for 
many years for other purposes. Another interesting approach would be to attempt to 
prolong and potentiate the effect of inosine. For this, a great understanding of purinergic 
metabolism is necessary in order to correctly and effectively approach this matter. 
5. Active drugs on adenosine receptors and their clinical applications  
Nowadays there is increasing interest in the therapeutic potential of adenosinergic 
compounds (including receptor agonists and antagonists, enzyme inhibitors and others), 
and many adenosine compounds have been evaluated.  
5.1 Adenosine receptor ligands and their potential as novel drugs 
Adenosine itself, for a long time, was the only adenosine agonist  used in humans. It is 
widely used in the treatment of paroxysmal supraventricular tachycardia (Adenocard®) due 
to its activation of A1R, and as a diagnostic for myocardial perfusion imaging (Adenoscan®) 
utilizing its A2AR-activating effects resulting in vasodilation (Müller & Jacobson, 2011). 
However, other A1R-selective agonists such as Selodenoson, Capadenoson e Tecadenoson 
have been clinically evaluated for the treatment of paroxysmal supraventricular tachycardia, 
atrial fibrillation, or angina pectoris (Müller & Jacobson, 2011). Still talking about 
cardiovascular disorders, selective A2AR agonist, Apadenoson, Binodenoson and 
Sonedenoson appears as candidates for clinical use (Awad et al., 2006; Desai et al., 2005; 
Udelson et al. 2004). These agonists are of interest as   vasodilator agents in cardiac imaging 
(Cerqueira, 2006) and inflammation suppressors. Accordingly, Regadenoson is already 
approved for diagnostic imaging (Iskandrian et al., 2007). A3R selective agonists are also 
currently in clinical trials and exhibit nanomolar affinity at the receptor, CF101 (Can-Fite 
Biopharma) and Cl-IB-MECA (CF102) are in trials for autoimmune inflammatory disorders 
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and for liver cancer, respectively. Two other A3R agonists CP-608,039 and its N6-(2,5-
dichlorobenzyl) analogue CP-532,903 were previously under development for 
cardioprotection. MRS3558 (CF502) is in preclinical development for the treatment of 
autoimmune disease (Avni et al., 2010; Wan et al., 2008). 
5.2 Adenosinergic drugs in pain clinical studies and practical 
Clinical studies confirm the pre-clinical trials showing that in neuropathic pain patients, 
adenosine was able to alleviate spontaneous pain, tactile and thermal allodynia, as well as 
thermal hyperalgesia (Qu et al., 1997). In addition, intravenous infusion of adenosine during 
breast surgery reduced the postoperative pain (Lynch et al., 2003; Sollevi et al., 1995). Spinal 
administration of adenosine and adenosine analogs in humans also exhibited analgesic 
effect. A phase I clinical safety study in healthy volunteers demonstrated that 1000 μg of 
adenosine given intrathecally lacked side effects and led to a significant decrease in mustard 
oil-induced inflammatory pain, in tourniquet induced ischemic pain, and decreased areas of 
secondary allodynia after skin inflammation (Rane et al., 1998).  
In another study, a single dose of 0.1 – 0.5 mg/kg of SDZ WAG 994 (adenosine A1R agonist), 
was evaluated in a phase I clinical study, and this compound was well tolerated. A dose of 1 
mg/kg was used in a randomized double-blind clinical trial to determine its efficacy in 
postoperative dental pain after third molar surgery. However, SDZ WAG 994 did not show 
significant difference from placebo and was not effective in attenuating postoperative pain 
after third molar surgery. On the other hand, at higher doses, the compound showed dose-
dependent adverse events (Seymour et al., 1999; Wagner et al., 1995; Yan et al., 2003). 
Another full high-affinity A1R agonists, GR79236X, was also evaluated in patients with 
dental pain after third molar extraction. Patients received a 15-min double-blind infusion 
containing 10 μg/kg of GR79236X, unfortunately, no evidence of efficacy of GR79236X was 
observed with this compound compared with placebo (Sneyd et al., 2007). Another A1R 
agonist GW493838 developed by GlaxoSmithKline, was evaluated in phase II clinical trials 
to determine its analgesic effect in patients with postherpetic neuralgia or peripheral nerve 
injury caused by trauma or surgery. However, further development of GW493838 has been 
discontinued (Nelsen et al., 2004; as cited in Elzein & Zablocki, 2008). 
Allosteric modulation of A1R function may also be an interesting tool. Accordingly, the A1R-
selective allosteric enhancer T-62, given orally was also shown to reduce hypersensitivity in 
carrageenan-inflamed rats, in addition, phase I clinical trials of T62 have been completed as 
a treatment for neuropathic pain (Childers et al., 2005). Therewithal, the A2AR agonist 
BVT.115959 from Biovitrum  completed the clinical trials for diabetic neuropathic pain and it 
was well tolerated but did not significantly improve pain symptoms (Biovitrum, 2005; 
Zylka, 2011). 
6. Conclusion and future directions 
This chapter presented a general and updated review about the purinergic system with 
emphasis in adenosine receptors (P1) and pain. It is possible to conclude that the 
modulation of this system and its receptors is quite important and interesting for the control 
of pain. Recent studies have approached this system in new ways and contributed to the 
development of this research field. Some clinical studies have been carried out with 
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purinergic drugs (adenosine analogs) and some studies have showed quite satisfactory 
effects, although others haven`t showed statistical difference between treated and non-
treated groups. Finally, the possibility of new drugs targeting the purinergic system to treat 
distinct kinds of pain reaching clinical trials in the next years is clear.  
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